

Cholinergic dysfunction in occupational manganese exposure

T. Noah Hutson^a, Susan Searles Nielsen^b, Natalie Senini^a, John O'Donnell^b, Hubert P. Flores^a, Tamara Hershey^{c,d}, Joel S. Perlmutter^{b,c,e,f,g,h}, Anil Kumar Soda^c, Stephen M. Moerlein^c, Zhude Tu^c, Michael Kasper^a, Lianne Sheppard^{i,j}, Brad A. Racette^{a,b,k}, Susan R. Criswell^{a,b,*}

^a Department of Neurology, Barrow Neurological Institute, 240 W Thomas Rd, Phoenix, AZ 85013, USA

^b Department of Neurology, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, USA

^c Department of Radiology, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, USA

^d Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, USA

^e Program in Physical Therapy, Washington University in St. Louis, St. Louis, MO, USA

^f Program in Occupational Therapy, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, USA

^g Department of Neuroscience, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, USA

^h Program in Physical Therapy, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, USA

ⁱ Department of Environmental and Occupational Health Sciences, University of Washington, School of Public Health, 3980 15th Ave NE, Seattle, WA 98195, USA

^j Department of Biostatistics, School of Public Health, University of Washington, 3980 15th Ave NE, Seattle, WA 98195, USA

^k School of Public Health, Faculty of Health Sciences, University of the Witwatersrand 27 St. Andrews Rd, Parktown 2193, South Africa

ARTICLE INFO

Keywords:

Manganese
PET
Cholinergic
Biomarkers
Neurotoxicology

ABSTRACT

Background and objective: Excessive exposure to manganese (Mn) produces a clinical syndrome of parkinsonism and cognitive impairment. However, our understanding of the mechanisms of Mn neurotoxicity remains limited. This study aimed to evaluate the relationships between Mn exposure, cholinergic function, and cognitive impairment in exposed workers.

Methods: We assessed brain cholinergic function using vesicular acetylcholine transporter (VAcHT) radiotracer (-)-(1-(8-(2-[(18F)fluoroethoxy]-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl) methanone (VAT) with positron emission tomography (PET) in 21 Mn-exposed workers. We estimated occupational Mn exposure from work histories and the MRI pallidal index. A cognitive control battery consisting of the Verbal Fluency (VF), Letter Number Sequencing (LNS), Two-Back Letter Task (2B), Go-No-Go (GnG), and Simon Task assessed cognitive function. We applied generalized linear models to Mn exposure, voxel-based cholinergic PET, and cognitive control measures, estimating coefficients for cholinergic-mediated associations between Mn and cognitive function. We utilized bootstrapping techniques to validate the mediation coefficients.

Results: Both Mn exposure metrics were associated with low cholinergic VAT binding in the caudate and cortical regions including the precuneus, pars triangularis, pars opercularis, middle temporal lobe, and entorhinal cortex. Regional cholinergic function mediated the relationship between Mn exposure and both the composite cognitive control score (mean of the 5 cognitive tests) [$\beta = -0.661$, 90 % confidence interval (CI) -2.130 , -0.032] and the individual VF assessment ($\beta = -0.944$, 90 % CI -2.157 , -0.065).

Discussion: Higher Mn exposure is associated with lower cholinergic activity in multiple brain regions. Cholinergic function also mediates a portion of the relationship between Mn exposure and cognitive control performance. Caudate and cortical cholinergic activity may be a biomarker of early Mn neurotoxicity and represent an important mechanism of cognitive dysfunction in parkinsonian syndromes.

* Corresponding author at: Department of Neurology, Barrow Neurological Institute, 240 W Thomas Rd, Phoenix, AZ 85013, USA.

E-mail addresses: timothy.hutson@commonspirit.org (T.N. Hutson), snielsen@wustl.edu (S.S. Nielsen), natalie.c.senini@gmail.com (N. Senini), jodonn@wustl.edu (J. O'Donnell), hugh.flores@barrowneuro.org (H.P. Flores), tammy@wustl.edu (T. Hershey), perlmutterjoel@wustl.edu (J.S. Perlmutter), soda@wustl.edu (A.K. Soda), moerleins@wustl.edu (S.M. Moerlein), zhudetu@wustl.edu (Z. Tu), michael.kasper44@gmail.com (M. Kasper), sheppard@uw.edu (L. Sheppard), brad.racette@barrowneuro.org (B.A. Racette), susan.criswell@barrowneuro.org (S.R. Criswell).

<https://doi.org/10.1016/j.neuro.2025.103313>

Received 5 February 2025; Received in revised form 27 August 2025; Accepted 31 August 2025

Available online 3 September 2025

0161-813X/© 2025 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Manganese (Mn) exposure impacts millions of people worldwide from occupational and environmental exposures secondary to industrial emissions and other sources of fossil fuel combustion (Neal and Guilarte, 2013). Mn is also a critical element in electronic vehicle batteries and the resulting massive quantities of battery waste are creating new sources of human exposure. Mn is a neurotoxicant that, in excess, produces a clinical syndrome of parkinsonism and cognitive impairment (Rodier, 1955). Cognitive impairment in Mn neurotoxicity increases in a dose-dependent manner with cumulative exposure and affects performance on tasks that require working memory, attention, concentration, cognitive flexibility, and visual spatial skills (Bowler et al., 2006; Bowler et al., 2015). While these associations are well described in Mn neurotoxicity, the underlying mechanisms are largely unknown.

The cholinergic system is physiologically essential in aspects of locomotion and cognition (Finkelstein et al., 2007). Current models of cognitive decline in idiopathic Parkinson disease (PD) and Parkinson disease dementia (PDD) propose a “dual-syndrome” or “two-hit” effect in which early dopaminergic deficits and later cholinergic deficits create the conditions for the development of cognitive impairment and dementia (Kehagia et al., 2013 Bohnen et al., 2015). As with PD and PDD, previous research in Mn neurotoxicity has focused on the involvement of dopaminergic systems despite evidence that Mn has demonstrable effects on the neuronal cholinergic synapse including choline uptake, choline acetyltransferase (ChAT) activity, acetylcholine release, and the regulation of acetylcholinesterase (AChE) (Finkelstein et al., 2007).

Early in-vivo molecular imaging studies of cholinergic systems in patients with PD and dementia were limited to PET tracers of AChE activity, which provided relatively poor regional specificity. PET imaging of vesicular acetylcholine transporter (VACHT) represents a major advance in imaging of the cholinergic system (Petrou et al., 2014). VACHT is only present in cholinergic cells and is expressed on presynaptic cholinergic terminals, where it appears to be tightly regulated with ChAT, as they share the same gene locus (Berrard et al., 1995). Pre-clinical and initial human studies using PET imaging VACHT radiotracers including (-)-(1-(8-(2-[(18F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone (VAT) demonstrate high brain uptake and excellent selectivity and specificity to human cholinergic nerve terminals (Petrou et al., 2014; O’donnell et al., 2024). This new generation of cholinergic tracers allows for improved assessment of cholinergic dysfunction, as indicated by lower VAT binding, in neurodegenerative conditions including Alzheimer disease (Aghourian et al., 2017) and PD (Slingerland et al., 2024).

The goal of this study is to use [(18F)VAT PET to measure in-vivo cholinergic function in Mn-exposed workers and examine its association with both Mn exposure and cognitive control performance. We previously observed poorer cognitive control performance in relation to higher cumulative occupational Mn exposure (Al-Lozi et al., 2017). In the present work, we hypothesize higher Mn exposure will be associated with lower regional cholinergic [(18F)VAT non-displaceable binding potentials (BP_{ND}) and subsequent poorer cognitive control performance in Mn-exposed workers. Given the similarities in clinical phenotype between Mn neurotoxicity, PD, and PDD we further hypothesize that underlying cholinergic dysfunction, as measured by VAT BP_{ND}, represents an important mechanism in cognitive control dysfunction associated with Mn exposure, i.e., that cholinergic dysfunction mediates at least part of the association between Mn exposure and cognitive control, and thus may provide critical insight into the common pathophysiology of these overlapping conditions.

2. Methods

2.1. Protocol approvals and participant consents

This study was approved by the Washington University Human Research Protection Office and conducted in accordance with the principles expressed in the Declaration of Helsinki. All participants gave written, informed consent prior to participation.

2.2. Participants

All participants (N = 21, two repeat studies for a total of 23 records) were from the United States (U.S.) Midwest and underwent [(18F)VAT PET between 1/9/2017 and 3/20/2023. We recruited participants from Mn-exposed workers who participated in our previous cohort study (Racette et al., 2017) from three Midwestern shipyards. The 21 Mn-exposed workers included 13 welders and eight workers from the same sites who worked around welding fume (Table 1). Possible worker occupations included or were a combination of the following: electrician, fabricator, fitter, inspector, machinist, millwright, painter/sandblaster, structural iron/steel worker, and technician. All reachable participants from the original union-based cohort (Racette et al., 2017) were offered participation in this study. Exclusion criteria were history of liver disease, stroke, brain tumor, or other condition that could compromise the neurologic examination; use of anti-parkinsonian medications, neuroleptics, or amphetamines that could affect VAT binding; and age < 18 years, all of which were uncommon.

2.3. Clinical assessments

Trained coordinators administered five tasks that assess cognitive control in one or more of its subdomains (e.g., response inhibition, working memory, fluency). These five tasks, described below, are validated measures that are frequently used in the cognitive neuroscience literature and previously used to assess cognitive control dysfunction in this cohort (Al-Lozi et al., 2017).

Table 1
Participant characteristics.

Characteristic	N = 21 n (%)
Sex	
Male	19 (90.4)
Female	2 (9.6)
Race and ethnicity	
Non-Hispanic White	21 (100)
Education	
Graduated High School/GED	17 (80.95)
Two Years of Higher Education	4 (19.05)
Age, years	
Mean (SD)	53.95 (13.95)
Min	31
Median	58
Max	73
Duration Mn exposure, years	
Mean (SD)	13.43 (13.72)
Min	1.25
Median	4.95
Max	41.09
Cumulative Mn exposure, mg Mn/m³-years	
Mean (SD)	1.88 (1.92)
Min	0.17
Median	0.69
Max	5.75
Pallidal Index	
Mean (SD)	112.07(4.56)
Min	103.28
Median	112.47
Max	121.91

SD = standard deviation; Mn = manganese.

(1) Verbal Fluency (VF): VF assesses response set shifting and fluency by having the participant list as many words as possible that fit a criterion in one minute. We used an age-adjusted total scaled score for this analysis (Mcdowd et al., 2011).

(2) Letter Number Sequencing (LNS): LNS assesses verbal working memory span. The participant must use working memory to repeat and rearrange randomly assorted letters and numbers into numerical and alphabetical order. We used the age-adjusted total scaled score as the primary outcome for the LNS (Gabrieli et al., 1996).

(3) Two-Back Letter Task (2B): 2B assesses working memory for verbal information. The participant decides as quickly as possible if a stimulus matches the one that appeared two trials earlier, testing both working memory and response inhibition. We used discriminability (mean accuracy rate minus the false positive response rate) as the primary outcome of the 2B test (Braver et al., 2001b).

(4) Go-No-Go (GnG): The GnG task assesses the ability to inhibit a prepotent response using verbal stimuli and requires active cognitive control processes such as conflict monitoring. The participant must exercise response inhibition to one of four stimuli as each stimulus appears in random order at fast intervals. We used discriminability as the primary GnG outcome (Braver et al., 2001a).

(5) Simon Task (Simon): This task is based on the Simon Effect in which an impertinent spatial stimulus will slow down reaction time to a target stimulus when the correct response button is spatially discordant with the impertinent, distracting stimulus (Wylie et al., 2010). The difference between the reaction time for congruent and incongruent trials was used in our analysis. Difference values were calculated so that lower values were associated with lower performance, thus the direction of scores corresponded to the other four tests.

To create a composite cognitive control summary score, we first calculated z-scores for each prespecified outcome variable for each task above. We then averaged these five z-scores (Al-Lozi et al., 2017). All scores (except the 2B test in which one participant failed to complete) were available for 18 of the 23 records. The remaining 5 participants did not undergo cognitive testing, as the protocol did not initially include the cognitive batteries.

2.4. Exposure assessment

All participants completed or updated a validated, structured questionnaire in person at the time of imaging, which included a detailed complete work history (Hobson et al., 2009). Using this information, we calculated cumulative lifetime occupational Mn exposure in mg Mn/m³-years, which takes into account both duration (years) and intensity (mg Mn/m³) of exposure (Racette et al., 2017). As a secondary measure of exposure we also obtained the MRI T1-weighted pallidal index (PI). Respirable Mn from occupational exposure deposits in the brain and can be detected on T1-weighted MRI, most prominently in the pallidum (Nelson et al., 1993). The T1 MRI PI is a well-established in-vivo marker of Mn exposure where a higher PI value is associated with greater welding exposure (Majewski et al., 2024; Criswell et al., 2012). Both the mg Mn/m³-years metric and PI were available for all participants (records), and corresponded with the date of the respective PET scan.

2.5. MRI acquisitions

All magnetic resonance imaging scanning was performed on a Siemens Magnetom Prisma 3T scanner (Erlangen, Germany) with a 12-channel head coil. We acquired high resolution three-dimensional (3-D) magnetization-prepared rapid gradient echo (MPRAGE) images on each participant (repetition time [TR]=2400 ms, inversion time [TI]=1000 ms, echo time [TE] = 3.14 ms, flip angle = 8°, 0.9 × 0.9 × 0.9 mm voxels). We used FreeSurfer™ (v5.3, Laboratory for Computational Neuroimaging, Charlestown MA) automated atlas-registration and volume segmentation from MPRAGE data to obtain the pallidal region and

the previously described white matter reference regions to calculate the MRI PI (Criswell et al., 2019) and [(18)F]VAT binding potential respectively (O'donnell et al., 2024). Volume and segmentation data were reviewed by a single investigator blinded to work history and clinical findings.

2.6. PET acquisition

PET was collected with a single Siemens ECAT EXACT HR+ scanner. Three retractable germanium 68 (68Ge) rod sources were used for transmission scans to measure individual attenuation factors. Transaxial and axial reconstructed spatial resolution at slice center were 4.3 mm and 4.1 mm full width half maximum (FWHM) in 3D mode (Brix et al., 1997). [(18) F]VAT was synthesized as previously described (Tu et al., 2015) and between 11.31 mCi - 14.82 mCi was intravenously injected into an arm vein over 30 s. We obtained 3-dimensional (3-D) dynamic PET images for 120 min beginning with radioligand injection, with eight 30 s frames, four 60 s frames, six 120 s frames, and twenty 300 s frames. PET scans were reconstructed with filtered back projection with ramp filter cut-off at the Nyquist frequency and included attenuation, scatter, deadtime, and randoms corrections as described previously (O'donnell et al., 2024).

2.7. PET image processing and analysis

2.7.1. Generation of voxel-wise parametric binding potential (BP) images

We segmented each participant's MR image into volumes of interest (VOIs) using Freesurfer™, as described above. The MR images were then co-registered to each participant's PET images to permit extraction of tissue activity curves (TACs) for each VOI from the set of dynamic PET images. Next, we utilized the white matter reference region to calculate voxel-wise non-displaceable binding potentials (BP_{ND}) using Logan analysis applied to TACs from 30 to 120 min post-injection (Logan, 2000). All steps were performed in native PET reconstruction space.

Following estimation of BP_{ND} per voxel, we co-registered parametric PET images to MRI space via a 6-parameter vector gradient linear transformation. The MR co-registered parametric images were then transformed into 711-2B atlas space (anisotropic voxel size 1.2 × 1.5 × 1.5 mm) by a second 6-parameter linear transform to bring all images into comparable space. We selected the 711-2B atlas based on the age distribution of the participants.

2.7.2. Voxel-defined spatial associations between exposure and VAT BP_{ND}

A voxel-based analysis was used to identify a map of voxels with robust associations between cumulative Mn exposure and VACHT binding. This newly defined VOI was used to more robustly examine associations between Mn exposure and cholinergic function from a data-driven, whole brain approach. To define this VOI, we first estimated voxel-wise generalized linear models (GLMs) between mg-Mn/m³-years and VAT BP_{ND}, adjusting for age as a linear term. A mask of brain volume specific to the present 23 PET studies was applied to the parametric GLM maps. We identified individual voxels exhibiting high absolute values of marked regression coefficients ($\hat{\beta}$) and R² values, and low (significant) p-values (Mikhno et al., 2008; Akamatsu et al., 2019). The first threshold, for the regression coefficient, was defined by generating normal distribution parameters, $\hat{\mu}$ (estimated as the mean of $\hat{\beta}$) and $\hat{\sigma}$ ($\hat{\beta}$ standard deviation), from all voxel GLM values in the masked volume. Voxels with coefficients with an absolute value greater than $\hat{\mu}$ by at least 0.5 $\hat{\sigma}$ passed to the next threshold. The second threshold, for R² values, was set to 0.5 (voxels with R² > 0.5 passed) and the third threshold, for p-values, was set to 0.05 (voxels with p < 0.05 passed through). This generated a pair of masks for voxels with significant 1) positive or 2) negative coefficients estimated from each GLM. We aggregated VAT BP_{ND} values of the newly defined VOIs (positive and negative β masks) by participant and a final GLM was applied to examine the relationship

between cumulative Mn exposure and this aggregated VAT BP_{ND} adjusted for age. As an alternative to our primary exposure variable, we conducted a secondary voxel-wise age-adjusted GLM analysis with PI and aggregated VAT BP_{ND}. We utilized these respective masks to ensure a relation between the respective Mn exposure metric and VAT BP_{ND}, as this is required for mediation to occur as hypothesized. An association between VAT BP_{ND} and cognitive control performance is also a requirement. However, we did not apply this latter requirement when defining our mask because we had several cognitive control performance variables and these data were available for fewer people.

2.7.3. Cholinergic VAT BP_{ND} as a potential mediator of the association between Mn exposure and cognitive control performance

We modeled the association between the respective Mn exposure metrics and cognitive control performance mediated through cholinergic function (VAT BP_{ND}). Using VAT BP_{ND} in the newly defined VOI, we estimated path-specific and total indirect effects of Mn exposure on cognitive control performance through cholinergic VAT BP_{ND} (Fig. 1). We similarly included age in each model due to its strong association with cumulative Mn exposure, VAT BP_{ND}, and cognitive control. Specifically, we leveraged the Preacher-Hayes bootstrapping method, generating 5000 bootstrap samples with replacement to determine if VAT BP_{ND} was a path-specific mediator and the combination of VAT BP_{ND} and age (age through VAT BP_{ND}) was a total mediator between Mn exposure and the cognitive control summary score (Hayes and Preacher, 2014). This non-parametric approach is optimized for smaller sample sizes, and leverages bootstrapping to define a percentile-based confidence interval of mediation coefficients, allowing for higher probability of statistically robust findings. We then repeated this analysis for each individual cognitive score.

For each bootstrap sample and cognitive control performance, we first estimated the model coefficients of exposure and age in relation to VAT BP_{ND}, respectively a_{exp} and a_{age} in the model below:

$$VAT_BP_{NDi} = \beta_1 + a_{exp} \cdot Exposure_i + a_{age} \cdot Age_i + \epsilon_1 \quad (1)$$

Where VAT_BP_{NDi} represents the aggregated binding potential in the newly defined VOI per participant, β_1 represents the intercept term, $Exposure_i$ and Age_i represent the Mn exposure metric and age (both as continuous variables) of each participant, and ϵ_1 represents the error term.

Next, we extracted the coefficient b from the following model:

$$Cog_i = \beta_2 + c_{exp} \cdot Exposure_i + c_{age} \cdot Age_i + b \cdot VAT_BP_{NDi} + \epsilon_2 \quad (2)$$

Where Cog_i is the value of the cognitive control summary score (or individual cognitive test) per participant, b represents the connection from cholinergic VAT BP_{ND} to cognitive control performance, and c_{exp} and c_{age} , respectively, represent direct effects (those not mediated through VAT BP_{ND}) of age and Mn exposure on cognitive control performance.




Fig. 1. Legend. Mediation model from Mn exposure to cognitive control performance through cholinergic VAT BP_{ND} while adjusting for age. Direct pathways of influence from Mn exposure and age on cognitive control function are shown in red (see Eq. (2)), while indirect (VAT BP_{ND} mediated) pathways are represented by the products of the blue and black arrows (also see Eq. (1)). Mn = manganese; VAT = (-)-(1-(8-(2-[(18F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone; BP_{ND} = non-displaceable binding potentials.

While some cognitive tests incorporated age into the scaled score, not all tests did. Thus, for our mediation analysis, we included age as a covariate to rule out its influence on VAT mediated relationship between Mn exposure and cognitive control.

We then took the products $a_{exp} \cdot b$ and $a_{age} \cdot b$ to determine the value of the indirect pathways respectively from Mn exposure and age to cognitive control performance through VAT BP_{ND}. We computed these coefficients and their products across the 5000 bootstrapped samples to estimate 90 % confidence intervals (CI) for indirect pathways (Hayes and Preacher, 2014). We used 90 % CIs (one-sided tests) based on the directional hypothesis that cholinergic neurons would be selectively impacted by Mn exposure leading to worse cognitive control performance (negative mediation coefficient). Given our specific directional hypothesis (that the mediation coefficient would be lower than 0), we used a 90 % CI as the probability of type 1 error for the specific single-tailed test for our alternative hypothesis is 95 %. Within the model that we developed, path-specific mediation refers to mediation of the Mn exposure-cognitive control by VAT BP_{ND}, while total mediation refers to the sum of the above in parallel with age (mediation by VAT BP_{ND} and age).

MATLAB 2024b was used for voxel-wise and cluster-based statistical analysis of the exposure data, images, and cognitive outcomes.

2.8. Data availability

Data from research participants in this study, who authorized sharing of their research data, will be made available to investigators with appropriate expertise and research support after publication of the primary aims of this study. All shared data will be deidentified and will be released in accordance with US regulations.

3. Results

3.1. Characteristics of participants

Nineteen workers were non-Hispanic White men and two were non-Hispanic White women (Table 1). All had similar education levels, either high school graduate/GED or two years of secondary education. Workers had a relatively wide range of duration of Mn exposure (1.25–41.09 years), but the majority had < 5 years of exposure. Workers had a similar age and sex distribution as compared to the larger cohort (Racette et al., 2017) from which they were recruited (data not shown). Participant cognitive control scores exhibited a wide range of scores, especially for the Simon test (Table 2).

Table 2
Cognitive control performance in Mn-exposed workers.

	N	Mean	Min	Median	Max
VF Scaled Score ^a	18	8.78	1.00	9.50	14.00
2B Discriminability ^b	17	0.52	-0.22	0.57	0.81
LNS Scaled Score ^a	18	10.11	6.00	9.00	16.00
GnG Discriminability ^c	18	0.91	0.66	0.92	1.00
Simon Reaction Time Interference Effect ^d	18	43.90	2.00	50.13	85.75
Cognitive Control Summary Score ^e	17	0.14	-4.20	-1.00	5.60

Mn = manganese; VF = Verbal Fluency; 2B = Two-Back Letter Task; LNS = Letter Number Sequence; GnG = Go-No-Go.

^a Age-adjusted total scaled score scaled to normative data.

^b Discriminability is defined as mean accuracy rate minus the false positive response rate.

^c Difference between accuracy and false alarm rate

^d The difference between the reaction time for congruent and incongruent reaction time was used.

^e Mean of the z-scores of each of the five tests.

3.2. Cumulative Mn exposure and cholinergic binding

Higher cumulative Mn exposure was associated (β : -0.074 , p -value: <0.001) with lower cholinergic VAT BP_{ND} within the data driven VOI including regions with both high magnitude of β -coefficient/ R^2 and low p -values (Fig. 2). Based on 3171 voxels that met these criteria, the largest concentrations of voxels within the negative β coefficient mask were in the left caudate, with representation in the right caudate, and cortical regions including the precuneus, pars triangularis, pars opercularis, middle temporal lobe, and entorhinal cortex (Fig. 3). The approximated Cohen's f^2 effect size of our covariates in the GLM based on the null and model deviances was 3.24, representing a significant explanatory value of cumulative Mn exposure and age on VAT BP_{ND}. Regional associations in space and direction of association were largely overlapping when we used PI rather than our cumulative Mn metric. We found no significant direct (positive) voxel-averaged associations between Mn exposure and cholinergic VAT BP_{ND}.

3.3. Mn-exposure, cholinergic binding, and cognitive control – results of the mediation analysis

High cumulative Mn exposures (mg-Mn/m³-years) mediated by VAT BP_{ND} were associated in specific ([VAT BP_{ND} & mg Mn/m³-years]- β coefficient -0.661 , 90 % CI -2.130 , -0.032) and total ([VAT BP_{ND} & mg Mn/m³-years/age]- β coefficient -0.671 , 90 % CI -2.113 , -0.032) paths with low cognitive control summary scores (Table 3). We additionally observed VAT-mediated age-adjusted associations in the same direction between cumulative Mn exposure and individual cognitive tests, however, this was only significant for VF ([VAT BP_{ND} & mg Mn/m³-years]- β coefficient -0.9443 , 90 % CI -2.1574 , -0.0651). Point estimates for the direct associations between cumulative Mn exposure and cognitive control summary and individual test scores were also negative but their 90 % CIs included zero.

In our secondary analysis that used the PI as the measure of Mn exposure, regions exhibiting associations between PI and cholinergic [(18F)VAT BP_{ND} largely overlapped with those obtained from the cumulative Mn (mg Mn/m³-year) analysis (Fig. 4), in addition to small clusters in the insular cortex and posterior isthmus cingulate cortex. Also consistent with the work history-based metric, we found indirect

associations in the VAT-mediated age-adjusted relationship between PI and cognitive control performance for specific ([VAT BP_{ND} & PI]- β coefficient -0.288 , 90 % CI -0.537 , -0.067) and total ([VAT BP_{ND} and PI/age]- β coefficient -0.491 , 90 % CI -0.820 , -0.142) mediation.

4. Discussion

This cross-sectional study investigates cholinergic function and cognitive control performance in relation to occupational Mn exposure and identifies multiple findings illustrating the importance of the cholinergic system in the pathophysiology of Mn neurotoxicity. First, using cholinergic [(18F)VAT PET, we demonstrate clear associations between Mn exposure and cholinergic activity within the brain. Specifically, higher levels of Mn exposure related to lower cholinergic VAT BP_{ND} in hundreds of voxels throughout the brain, but these associations were most evident in the caudate and cortical regions including the precuneus, pars triangularis, pars opercularis, middle temporal lobe, and entorhinal cortex. Second, leveraging bootstrapping techniques for the small sample size, we detected mediation effects of regional cholinergic function as measured by VAT BP_{ND} in the relationship between Mn exposure and cognitive control performance. The nature of this indirect effect suggests that the relationship between cholinergic function and cognitive control performance may be affected by a region-specific sensitivity to Mn neurotoxicity. These associations were supported using the T1-weighted PI as an alternative measure of Mn exposure with strikingly similar regional results.

Further, we identified these changes in in-vivo cholinergic activity and cognitive performance in a cohort with an estimated mean time-weighted Mn exposure of 0.14 mg Mn/m³. This estimated exposure is substantially lower than the US Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit for Mn of 5 mg Mn/m³ (Occupational Safety And Health Administration Osha, 2020) and more consistent with the American Conference of Governmental Industrial Hygienists (ACGIH) time-weighted average threshold limit value for inspirable Mn of 0.1 mg Mn/m³ (American Conference of Governmental Industrial, 2013). Given that we observe in-vivo changes in cholinergic function and lower cognitive performance scores in subjectively normal workers at levels slightly above the ACGIH standard, our study provides additional support for reducing the OSHA




Fig. 2. Legend. GLM parameter maps (estimated between mg-Mn/m³-year and cholinergic VAT BP_{ND} with age adjustment) per voxel on a selected slice depicting values for the three criteria for voxel selection: A. magnitude of the negative beta coefficients; B. r^2 values; and C. p -values. Voxels selected for final cluster would exhibit high (red or yellow) values for panels A and B while exhibiting low (green or blue) p -values for panel C. GLM = generalized linear models; Mn = manganese; VAT = $(-)-(1-(8-(2-[(18F)fluoroethoxy]-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone$; BP_{ND} = non-displaceable binding potentials.




Fig. 3. Legend. A. Representative slice of a VOI cluster (in red) superimposed on the T1 MPRAGE MR atlas, and B. The association between cumulative Mn exposure (mg-Mn/m³-year) and cholinergic VAT BP_{ND} for the full VOI represented in A in red. VOI = volume of interest; MPRAGE = magnetization-prepared rapid gradient echo; Mn = manganese; VAT = (-)-(1-(8-(2-[(18)F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone; BP_{ND} = non-displaceable binding potentials.

Table 3
VAT BP_{ND} mediation between Mn exposure and cognitive control performance.

		Median β	90 % CI	
VF Scaled Score	mg Mn/ m ³ -years	-0.9443*	-2.1574	-0.0651
	Age (years)	-0.0037	-0.0430	0.0224
	Total	-0.9553*	-2.1554	-0.0655
2B Discriminability	mg Mn/ m ³ -years	-0.0161	-0.0762	0.1121
	Age (years)	-0.0002	-0.0025	0.0005
	Total	-0.0163	-0.0770	0.1114
LNS Scaled Score	mg Mn/ m ³ -years	-0.2186	-1.1219	0.6210
	Age (years)	-0.0002	-0.0145	0.0193
	Total	-0.2203	-1.1024	0.6253
GnG Discriminability	mg Mn/ m ³ -years	-0.0089	-0.0704	0.0156
	Age (years)	0.0000	-0.0004	0.0012
	Total	-0.0089	-0.0696	0.0159
Simon Reaction Time Interference Effect	mg Mn/ m ³ -years	-2.6138	-22.7866	7.4858
	Age (years)	-0.0117	-0.2589	0.1619
	Total	-2.6648	-22.7219	7.4576
Cognitive Control Summary Score ^a	mg Mn/ m ³ -year	-0.661*	-2.130	-0.032
	Age (years)	-0.002	-0.031	0.026
	Total	-0.671*	-2.113	-0.032

Median β is taken from 5000 bootstrapped β estimates; Coefficients are not comparable across individual tests.
*indicates significant mediation (CI excludes 0). ^aMean of the z-scored VF, 2B, LNS, GnG, and Simon tests.
BP_{ND} = non-displaceable binding potentials; Mn = manganese; CI = confidence interval; VF = Verbal Fluency; 2B = Two-Back Letter Task; LNS = Letter Number Sequence; GnG = Go-No-Go.

Permissible Exposure Limit to the ACHIG threshold limit value. Cholinergic [(18)F]VAT uptake may represent an in-vivo biomarker of early cognitive or even subclinical Mn neurotoxicity, although the latter




Fig. 4. Legend. Representative slice of VOI clusters for mg-Mn/m³-year/cholinergic VAT BP_{ND} (in red) and PI/ VAT BP_{ND} (in yellow) associations superimposed on 711-2B atlas. Areas of overlap are represented in orange. VOI = volume of interest; Mn = manganese; VAT = (-)-(1-(8-(2-[(18)F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone; BP_{ND} = non-displaceable binding potentials; PI = pallid index.

would require further study.
Occupational Mn exposure results in Mn deposits throughout the brain with some of the highest concentrations in the basal ganglia, frontal cortex, and cerebellum (Monsivais et al., 2024). Hypothesized mechanisms of toxicity include impaired calcium homeostasis (Ijomone et al., 2019), mitochondrial dysfunction (Martinez-Finley et al., 2013), neuroinflammation, (Harischandra et al., 2019) altered proteostasis, (Harischandra et al., 2019) impaired microRNA function, (Wallace et al., 2020) and altered metabolism of neurotransmitters including ACh (Soares et al., 2020). Mechanistically, animal and molecular models demonstrate the diffuse effects of Mn on multiple areas of the neuronal

cholinergic synapse that could contribute to cholinergic dysfunction. Mn inhibits presynaptic striatal and extrastriatal choline uptake in the caudate, putamen, hippocampus, frontal and parietal cortices, (Eriksson et al., 1984) and once within the nerve terminal, Mn appears to have direct effects on the quantal release of acetylcholine into the synaptic cleft (Kita et al., 1981; Glitsch and Pott, 1978). Further, Mn has regional and temporal effects on the degradation of acetylcholine (ACh) by regulating acetylcholinesterase (AChE) activity (Santos et al., 2012; Zhang et al., 2001). Interestingly, Mn decreases striatal and midbrain presynaptic choline acetyltransferase (ChAT) activity in the striatal cholinergic terminals of chronically exposed rats (Lai et al., 1981). In our study, we identify a similar dose-dependent association between VAT binding of VACHT (which is tightly regulated with ChAT) in the caudate and cortical regions of Mn-exposed workers in association with higher levels of cumulative Mn exposure.

Additionally, we identified that lower cholinergic activity underlies a component of the relationship between higher Mn exposure and lower cognitive control including lower performance on the VF task. These findings are consistent with our previous studies in which cognitive control performance was related to environmental and occupational Mn exposure (Al-Lozi et al., 2017; Racette et al., 2022) and the larger literature documenting more generalized cognitive deficits including, but not limited to visual spatial skills, working memory, cognitive flexibility, attention, and concentration in both human (Bowler et al., 2003; Bowler et al., 2006; Park et al., 2009; Park, 2013; Vlasak et al., 2023) and controlled animal models (Schneider et al., 2015; Schneider et al., 2013; Newland and Weiss, 1992; Burton and Guilarte, 2009; Smith and Strupp, 2023; Kern et al., 2010). Cognitive control encompasses the goal-oriented ability to manipulate information, to distinguish and identify relevant data, to be flexible, and to self-regulate to achieve high order objectives including adaptation, prioritization, and organization (Botvinick and Braver, 2015; Rabinovici et al., 2015; Al-Lozi et al., 2017). Identifying deficits in these areas has direct relevance to workers and exposed individuals as impairment in these domains could have detrimental effects on work performance and daily function. Further, cholinergic neurons are physiologically essential in locomotion and cognition (Finkelstein et al., 2007) and gradual age-associated loss of cholinergic function has been implicated in age-related functional decline and cognitive impairment (Schliebs and Arendt, 2006). Severe loss of cholinergic neurons ultimately results in clinical dementia (Schliebs and Arendt, 2006). Here we demonstrate exposure to Mn relates to lower cholinergic activity and poorer cognitive control/individual VF performance, above and beyond the expected effects of age. Longitudinal investigations will be necessary to see if this effect progresses to include deficits on individual memory tasks and increases the risk for age-related functional decline and/or neurodegeneration including dementia.

In this study, cumulative Mn exposure was strongly related to lower cholinergic activity in the caudate, precuneus, pars triangularis, pars opercularis, middle temporal lobe, and entorhinal cortex. The caudate, in particular, has been implicated in the pathophysiology of Mn as an area demonstrating higher T1 MRI signal (Mn deposition) and dopaminergic dysfunction (Criswell et al., 2018; Criswell et al., 2012). Similarly, as part of the mesocortical dopaminergic circuit, the caudate is also heavily implicated in cognitive control dysfunction associated with PD (Hirano, 2021; Bohnen et al., 2015). However, while striatal dopaminergic denervation is common even in PD patients without any cognitive impairment, the presence of cortical cholinergic denervation is more specific to those with cognitive deficits (Bohnen et al., 2015, 2006) demonstrating the complex functional interactions between anatomically distinct regions within the brain's dopaminergic and cholinergic networks. The dual presence of striatal dopamine and cortical cholinergic denervation in PD patients with cognitive impairment highlights the complex, multi-system, multi-transmitter deficiencies likely present in PD and related parkinsonian conditions. The caudate nucleus contains a large number of cholinergic interneurons which are involved in

attention, goal-directed actions, habit formation, and behavioral flexibility through modulation of all striatal cell types including D1R and D2R medium spiny neuron (Pisani et al., 2007; Bohnen and Albin, 2011). However, little is known about interneuron behavior in PD and this may represent an important area of future exploration. Our findings demonstrating lower cholinergic activity in association with cognitive dysfunction in Mn neurotoxicity, also emphasize the need to study non-dopaminergic neurotransmitters when investigating basal ganglia mediated cognitive control dysfunction (McKeown and Peavy, 2015). Future, multi-modal studies including multiple neurotransmitters may represent complementary biomarkers of both motor and cognitive deficits associated with Mn exposure and provide a better mechanistic understanding of pathophysiology of Mn neurotoxicity and parkinsonian syndromes.

5. Limitations

This study has several potential limitations. Welding fume contains multiple gases and elements, including iron, lead, chromium and nickel; (NIOSH, 1988; Abdullahi and Sani, 2020; Li et al., 2004) therefore, we cannot fully exclude a contribution from other potential welding fume neurotoxicants. Our study relies on Mn exposure estimates based on work histories; however, we observed a similar pattern of results with the T1 MRI PI. Our sample size is limited in this study, but we observed effects, nonetheless. The models we specified make assumptions about linearity in the inter-relationships between Mn exposure, age, cholinergic VAT BP_{ND}, and cognitive control performance. These assumptions were generally supported by the data, but this approach will not capture non-linear relationships. We also did not consider interactions between our variables or potential confounders other than age. To make our mediation findings more statistically robust, we leveraged bootstrapping techniques. This approach did not depend on sample-wise assumptions of normality for claims of statistical significance. Another consideration is that for mediation analysis, we leveraged regions with Mn exposure and VAT BP_{ND} associations, without incorporating cognition into our region selection. We feel this approach is justified as the regions with the highest propensity to be affected by Mn exposure would likely also have strong associations with cognitive control dysfunction and would best demonstrate a directed path from Mn exposure to altered cognition control ability. Finally, this is a cross-sectional study examining the cholinergic system via [(18)F]VAT PET and, thus, does not address whether Mn induces progressive cognitive decline which would be suggestive of a neurodegenerative phenotype. Future longitudinal studies including serial cognitive evaluations in conjunction with multi-radioligand PET studies, may be helpful in further elucidating the underlying mechanisms of Mn neurotoxicity.

6. Conclusion

In summary, we demonstrated that higher Mn exposure relates to lower cholinergic activity in the caudate, the precuneus, pars triangularis, pars opercularis, middle temporal lobe, and entorhinal cortex, and lower cholinergic activity in these regions mediates a portion of the relationship between Mn exposure and cognitive control function. Caudate and cortical cholinergic activity may be of particular interest as a biomarker of Mn neurotoxicity and key regions in understanding the underlying mechanism of cognitive control dysfunction in parkinsonian syndromes including Mn neurotoxicity, PD, and PDD.

CRedit authorship contribution statement

Natalie Senini: Formal analysis. **Susan Searles Nielsen:** Writing – review & editing, Methodology, Formal analysis. **Brad A. Racette:** Writing – review & editing, Methodology, Investigation, Conceptualization. **T. Noah Hutson:** Writing – review & editing, Writing – original draft, Supervision, Software, Methodology, Investigation, Formal

analysis, Conceptualization. **Lianne Sheppard:** Writing – review & editing, Methodology. **Michael Kasper:** Writing – review & editing, Software, Methodology, Formal analysis, Data curation, Conceptualization. **Tamara Hershey:** Writing – review & editing, Validation, Data curation, Conceptualization. **Hubert P. Flores:** Writing – review & editing, Software, Formal analysis, Data curation. **John O'Donnell:** Writing – review & editing, Formal analysis. **Susan R. Criswell:** Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Zhude Tu:** Methodology, Data curation. **Stephen M. Moerlein:** Writing – review & editing, Data curation, Conceptualization. **Anil Kumar Soda:** Writing – review & editing, Data curation. **Joel S. Perlmutter:** Methodology, Data curation.

Funding statement

This work was supported by the following NIH and Foundation grants: R01ES021488, R01ES029524, K23ES021444, K24ES017765, K01ES028295, R01ES013743, R01NS075527, R01ES021488-02S1, P42ES004696, RF1NS075321, and ICTS UL1RR024992, the American Parkinson Disease Association (APDA) Advanced Research Center at Washington University in St. Louis, the Missouri Chapter of the APDA, the Paula and Rodger Riney Foundation, and the Barnes-Jewish Hospital Foundation. These sponsors had no involvement in the study design; collection, analysis, or interpretation of the data; writing of the report; or decision to submit this work for publication.

Declaration of Competing Interest

T. Noah Hutson reports no disclosures relevant to the manuscript; S. Searles Nielsen receives support from the following government and non-governmental organizations: R01ES029524/NIEHS R01ES029524, R01ES026891, R01ES026891-S1, R01ES025991, R01ES025991-S1, K01ES028295, the US Department of Defense PD190057, and MJFF 000939, 020718; N. Senini reports no disclosures relevant to the manuscript; J. O'Donnell reports no disclosures relevant to the manuscript; H.P. Flores reports no disclosures relevant to the manuscript; T. Hershey receives support from the following government organizations: NIEHS R01ES021488, R01ES029524, R01ES013743; J. S. Perlmutter receives support from the following government and non-governmental organizations: NIA/NINDS RF1NS075321, the American Parkinson Disease Association (APDA) Advanced Research Center at Washington University, the Missouri Chapter of the APDA, the Riney Fund, and the Barnes-Jewish Hospital Foundation; A. K. Soda reports no disclosures relevant to the manuscript; S. M. Moerlein reports no disclosures relevant to the manuscript; Z. Tu receives support from the following government organizations: NIA/NINDS R01NS075527; M. Kasper reports no disclosures relevant to the manuscript; L. Sheppard receives research support from the following government organizations: R01ES029524; B. A. Racette receives research support from the following government and non-governmental organizations: MJFF 000939, 020718, NIEHS R01ES025991, R01ES025991-02S1, R01ES030937-S1, R01ES029524, NIOSH R01OH011661, Department of Defense PD190057, Hope Center for Neurologic Disorders (Washington University), and the Kemper and Ethel Marley Foundation. B.A. Racette has received honoraria (personal compensation) for service on the National Advisory Environmental Health Sciences Council for NIEHS; S.R. Criswell receives research support from the following government and nongovernmental organizations: NIEHS R01ES029524, R01OH011661, R01ES021488.

Data availability

Data will be made available on request.

References

- Abdullahi, I.L., Sani, A., 2020. Welding fumes composition and their effects on blood heavy metals in albino rats. *Toxicol. Rep.* 7, 1495–1501.
- Aghourian, M., Legault-Denis, C., Soucy, J.P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P., Bedard, M.A., 2017. Quantification of brain cholinergic denervation in alzheimer's disease using PET imaging with [(18)F]-FE0BV. *Mol. Psychiatry* 22, 1531–1538.
- Akamatsu, G., Ikari, Y., Ohnishi, A., Matsumoto, K., Nishida, H., Yamamoto, Y., Senda, M., Japanese Alzheimer's Disease Neuroimaging, I., 2019. Voxel-based statistical analysis and quantification of amyloid PET in the Japanese alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. *EJNMMI Res.* 9, 91.
- Al-Lozi, A., Nielsen, S.S., Hershey, T., Birke, A., Checkoway, H., Criswell, S.R., Racette, B.A., 2017. Cognitive control dysfunction in workers exposed to manganese-containing welding fume. *Am. J. Ind. Med.* 60, 181–188.
- American Conference Of Governmental Industrial, H. 2013. Annual Reports for the Year 2012: Committees on Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs). Cincinnati, OH: ACGIH.
- Berrard, S., Varoqui, H., Cervini, R., Israel, M., Mallet, J., Diebler, M.F., 1995. Coregulation of two embedded gene products, choline acetyltransferase and the vesicular acetylcholine transporter. *J. Neurochem.* 65, 939–942.
- Bohnen, N.I., Albin, R.L., 2011. The cholinergic system and parkinson disease. *Behav. Brain Res.* 221, 564–573.
- Bohnen, N.I., Albin, R.L., Muller, M.L., Petrou, M., Kotagal, V., Koeppe, R.A., Scott, P.J., Frey, K.A., 2015. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of parkinson disease and evidence of interaction effects. *JAMA Neurol.* 72, 194–200.
- Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B.J., Constantine, G.M., Mathis, A., C.H., Davis, J.G., Moore, R.Y., Dekosky, S.T., 2006. Cognitive correlates of cortical cholinergic denervation in parkinson's disease and parkinsonian dementia. *J. Neurol.* 253, 242–247.
- Botvinick, M., Braver, T., 2015. Motivation and cognitive control: from behavior to neural mechanism. *Annu. Rev. Psychol.* 66, 83–113.
- Bowler, R.M., Gysens, S., Diamond, E., Booty, A., Hartney, C., Roels, H.A., 2003. Neuropsychological sequelae of exposure to welding fumes in a group of occupationally exposed men. *Int. J. Hyg. Environ. Health* 206, 517–529.
- Bowler, R.M., Gysens, S., Diamond, E., Nakagawa, S., Drezgic, M., Roels, H.A., 2006. Manganese exposure: neuropsychological and neurological symptoms and effects in welders. *Neurotoxicology* 27, 315–326.
- Bowler, R.M., Kornblith, E.S., Gocheva, V.V., Colledge, M.A., Bollweg, G., Kim, Y., Beseler, C.L., Wright, C.W., Adams, S.W., Lobdell, D.T., 2015. Environmental exposure to manganese in air: associations with cognitive functions. *Neurotoxicology* 49, 139–148.
- Braver, T.S., Barch, D.M., Gray, J.R., Molfese, D.L., Snyder, A., 2001a. Anterior cingulate cortex and response conflict: effects of frequency, inhibition and errors. *Cereb. Cortex* 11, 825–836.
- Braver, T.S., Barch, D.M., Kelley, W.M., Buckner, R.L., Cohen, N.J., Miezin, F.M., Snyder, A.Z., Ollinger, J.M., Akbudak, E., Conturo, T.E., Petersen, S.E., 2001b. Direct comparison of prefrontal cortex regions engaged by working and long-term memory tasks. *Neuroimage* 14, 48–59.
- Brix, G., Zaers, J., Adam, L.E., Bellemann, M.E., Ostertag, H., Trojan, H., Haberkorn, U., Doll, J., Oberdorfer, F., Lorenz, W.J., 1997. Performance evaluation of a whole-body PET scanner using the NEMA protocol. *National electrical manufacturers association. J. Nucl. Med.* 38, 1614–1623.
- Burton, N.C., Guilarte, T.R., 2009. Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. *Environ. Health Perspect.* 117, 325–332.
- Criswell, S.R., Nielsen, S.S., Warden, M., Perlmutter, J.S., Moerlein, S.M., Flores, H.P., Huang, J., Sheppard, L., Seixas, N., Checkoway, H., Racette, B.A., 2018. [(18)F]FDOPA positron emission tomography in manganese-exposed workers. *Neurotoxicology* 64, 43–49.
- Criswell, S.R., Nielsen, S.S., Warden, M.N., Flores, H.P., Lenox-Krug, J., Racette, S., Sheppard, L., Checkoway, H., Racette, B.A., 2019. MRI signal intensity and parkinsonism in Manganese-Exposed workers. *J. Occup. Environ. Med.* 61, 641–645.
- Criswell, S.R., Perlmutter, J.S., Huang, J.L., Golchin, N., Flores, H.P., Hobson, A., Aschner, M., Erikson, K.M., Checkoway, H., Racette, B.A., 2012. Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. *Occup. Environ. Med.* 69, 437–443.
- Eriksson, H., Morath, C., Heilbronn, E., 1984. Effects of manganese on the nervous system. *Acta Neurol. Scand. Suppl.* 100, 89–93.
- Finkelstein, Y., Milatovic, D., Aschner, M., 2007. Modulation of cholinergic systems by manganese. *Neurotoxicology* 28, 1003–1014.
- Gabrieli, J.D.E., Singh, J., Stebbins, G.T., Goetz, C.G., 1996. Reduced working memory span in parkinson's disease: evidence for the role of a frontostriatal system in working and strategic memory. *Neuropsychology* 10, 322–332.
- Glitsch, H.G., Pott, L., 1978. Effect of divalent cations on acetylcholine release from cardiac parasympathetic nerve endings. *Pflug. Arch.* 377, 57–63.
- Harischandra, D.S., Ghaisas, S., Zenitsky, G., Jin, H., Kanthasamy, A., Anantharam, V., Kanthasamy, A.G., 2019. Manganese-Induced neurotoxicity: new insights into the triad of protein misfolding, mitochondrial impairment, and neuroinflammation. *Front. Neurosci.* 13, 654.
- Hayes, A.F., Preacher, K.J., 2014. Statistical mediation analysis with a multicategorical independent variable. *Br. J. Math. Stat. Psychol.* 67, 451–470.
- Hirano, S., 2021. Clinical implications for dopaminergic and functional neuroimaging research in cognitive symptoms of parkinson's disease. *Mol. Med.* 27, 40.
- Hobson, A.J., Sterling, D.A., Emo, B., Evanoff, B.A., Sterling, C.S., Good, L., Seixas, N., Checkoway, H., Racette, B.A., 2009. Validity and reliability of an occupational

- exposure questionnaire for parkinsonism in welders. *J. Occup. Environ. Hyg.* 6, 324–331.
- Ijomone, O.M., Aluko, O.M., Okoh, C.O.A., Martins, A.C., J.R., Aschner, M., 2019. Role for calcium signaling in manganese neurotoxicity. *J. Trace Elem. Med. Biol.* 56, 146–155.
- Kehagia, A.A., Barker, R.A., Robbins, T.W., 2013. Cognitive impairment in parkinson's disease: the dual syndrome hypothesis. *Neurodegener. Dis.* 11, 79–92.
- Kern, C.H., Stanwood, G.D., Smith, D.R., 2010. Prewaning manganese exposure causes hyperactivity, disinhibition, and spatial learning and memory deficits associated with altered dopamine receptor and transporter levels. *Synapse* 64, 363–378.
- Kita, H., Narita, K., Van Der Kloot, W., 1981. Tetanic stimulation increases the frequency of miniature end-plate potentials at the frog neuromuscular junction in Mn²⁺, CO₂ +, and Ni²⁺-saline solutions. *Brain Res.* 205, 111–121.
- Lai, J.C., Leung, T.K., Lim, L., 1981. Brain regional distribution of glutamic acid decarboxylase, choline acetyltransferase, and acetylcholinesterase in the rat: effects of chronic manganese chloride administration after two years. *J. Neurochem.* 36, 1443–1448.
- Li, G.J., Zhang, L.L., Lu, L., Wu, P., Zheng, W., 2004. Occupational exposure to welding fume among welders: alterations of manganese, iron, zinc, copper, and lead in body fluids and the oxidative stress status. *J. Occup. Environ. Med.* 46, 241–248.
- Logan, J., 2000. Graphical analysis of PET data applied to reversible and irreversible tracers. *Nucl. Med. Biol.* 27, 661–670.
- Majewski, M., Piwko, K., Ordak, M., Muszynska, E., Nasierowski, T., Bujalska-Zadrozny, M., 2024. Magnetic resonance imaging and manganese: a narrative review and laboratory recommendations. *J. Clin. Med.* 13.
- Martinez-Finley, E.J., Gavin, C.E., Aschner, M., Gunter, T.E., 2013. Manganese neurotoxicity and the role of reactive oxygen species. *Free Radic. Biol. Med.* 62, 65–75.
- McDowd, J., Hoffman, L., Rozek, E., Lyons, K.E., Pahwa, R., Burns, J., Kemper, S., 2011. Understanding verbal fluency in healthy aging, alzheimer's disease, and parkinson's disease. *Neuropsychology* 25, 210–225.
- McKeown, M.J., Peavy, G.M., 2015. Biomarkers in parkinson disease: it's time to combine. *Neurology* 84, 2392–2393.
- Mikhno, A., Devanand, D., Pelton, G., Cuasay, K., Gunn, R., Upton, N., Lai, R.Y., Libri, V., Mann, J.J., Parsey, R.V., 2008. Voxel-based analysis of 11C-PIB scans for diagnosing alzheimer's disease. *J. Nucl. Med.* 49, 1262–1269.
- Monsivais, H., Yeh, C.L., Edmondson, A., Harold, R., Snyder, S., Wells, E.M., Schmidt-Wilcke, T., Foti, D., Zaubner, S.E., Dydak, U., 2024. Whole-brain mapping of increased manganese levels in welders and its association with exposure and motor function. *Neuroimage* 288, 120523.
- Neal, A.P., Guilarte, T.R., 2013. Mechanisms of lead and manganese neurotoxicity. *Toxicol. Res.* 2, 99–114.
- Nelson, K., Golnick, J., Korn, T., Angle, C., 1993. Manganese encephalopathy: utility of early magnetic resonance imaging. *Br. J. Ind. Med.* 50, 510–513.
- Newland, M.C., Weiss, B., 1992. Persistent effects of manganese on effortful responding and their relationship to manganese accumulation in the primate globus pallidus. *Toxicol. Appl. Pharmacol.* 113, 87–97.
- Niosh 1988. Criteria for a Recommended Standard: Welding, Brazing, and Thermal Cutting. In: US Department of Health and Human Services, Public Health Service, Centers for Disease Control & National Institute for Occupational Safety and Health (eds.) NIOSH. Cincinnati, OH.
- Occupational Safety And Health Administration (OSHA) 2020. TABLE Z-1 Limits for Air Contaminants. In: UNITED STATES DEPARTMENT OF LABOR (ed.) Code of Federal Regulations Title 29, Part 1910.1000, Table Z-1. Government Publishing Office.
- O'donnell, J.L., Soda, A.K., Jiang, H., Norris, S.A., Maiti, B., Karimi, M., Campbell, M.C., Moerlein, S.M., Tu, Z. & Perlmutter, J.S. 2024. PET Quantification of [(18)F]VAT in Human Brain and Its Test-Retest Reproducibility and Age Dependence. *J Nucl Med*, 65, 956-961.
- Park, R.M., 2013. Neurobehavioral deficits and parkinsonism in occupations with manganese exposure: a review of methodological issues in the epidemiological literature. *Saf. Health Work* 4, 123–135.
- Park, R.M., Bowler, R.M., Roels, H.A., 2009. Exposure-response relationship and risk assessment for cognitive deficits in early welding-induced manganese. *J. Occup. Environ. Med.* 51, 1125–1136.
- Petrou, M., Frey, K.A., Kilbourn, M.R., Scott, P.J., Raffel, D.M., Bohnen, N.I., Muller, M. L., Albin, R.L., Koeppe, R.A., 2014. In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. *J. Nucl. Med.* 55, 396–404.
- Pisani, A., Bernardi, G., Ding, J., Surmeier, D.J., 2007. Re-emergence of striatal cholinergic interneurons in movement disorders. *Trends Neurosci.* 30, 545–553.
- Rabinovici, G.D., Stephens, M.L., Possin, K.L., 2015. Executive dysfunction. *Continuum* 21, 646–659.
- Racette, B.A., Nelson, G., Dlamini, W.W., Hershey, T., Prathibha, P., Turner, J.R., Checkoway, H., Sheppard, L., Searles Nielsen, S., 2022. Environmental manganese exposure and cognitive control in a South African population. *Neurotoxicology* 89, 31–40.
- Racette, B.A., Searles Nielsen, S., Criswell, S.R., Sheppard, L., Seixas, N., Warden, M.N., Checkoway, H., 2017. Dose-dependent progression of parkinsonism in manganese-exposed welders. *Neurology* 88, 344–351.
- Rodier, J., 1955. Manganese poisoning in Moroccan miners. *Br. J. Ind. Med.* 12, 21–35.
- Santos, D., Milatovic, D., Andrade, V., Batoreu, M.C., Aschner, M., Marreilha Dos Santos, A.P., 2012. The inhibitory effect of manganese on acetylcholinesterase activity enhances oxidative stress and neuroinflammation in the rat brain. *Toxicology* 292, 90–98.
- Schliebs, R., Arendt, T., 2006. The significance of the cholinergic system in the brain during aging and in alzheimer's disease. *J. Neural Transm. (Vienna)* 113, 1625–1644.
- Schneider, J.S., Williams, C., Ault, M., Guilarte, T.R., 2013. Chronic manganese exposure impairs visuospatial associative learning in non-human primates. *Toxicol. Lett.* 221, 146–151.
- Schneider, J.S., Williams, C., Ault, M., Guilarte, T.R., 2015. Effects of chronic manganese exposure on attention and working memory in non-human primates. *Neurotoxicology* 48, 217–222.
- Slingerland, S., Van Der Zee, S., Carli, G., Slomp, A.C., Boertien, J.M., D'angremont, E., Bohnen, N.I., Albin, R.L., Van Laar, T., 2024. Cholinergic innervation topography in GBA-associated de novo parkinson's disease patients. *Brain* 147, 900–910.
- Smith, D.R., Strupp, B.J., 2023. Animal models of childhood exposure to lead or manganese: evidence for impaired attention, impulse control, and affect regulation and assessment of potential therapies. *Neurotherapeutics* 20, 3–21.
- Soares, A.T.G., Silva, A.C., Tinkov, A.A., Khan, H., Santamaria, A., Skalnaya, M.G., Skalny, A.V., Tsatsakis, A., Bowman, A.B., Aschner, M., Avila, D.S., 2020. The impact of manganese on neurotransmitter systems. *J. Trace Elem. Med. Biol.* 61, 126554.
- Tu, Z., Zhang, X., Jin, H., Yue, X., Padakanti, P.K., Yu, L., Liu, H., Flores, H.P., Kaneshige, K., Parsons, S.M., Perlmutter, J.S., 2015. Synthesis and biological characterization of a promising F-18 PET tracer for vesicular acetylcholine transporter. *Bioorg. Med. Chem.* 23, 4699–4709.
- Vlasak, T., Dujlovic, T., Barth, A., 2023. Manganese exposure and cognitive performance: a meta-analytical approach. *Environ. Pollut.* 332, 121884.
- Wallace, D.R., Taalab, Y.M., Heinze, S., Tariba Lovakovic, B., Pizent, A., Renieri, E., Tsatsakis, A., Farooqi, A.A., Javorac, D., Andjelkovic, M., Bulat, Z., Antonijevic, B., Buha Djordjevic, A., 2020. Toxic-Metal-Induced alteration in miRNA expression profile as a proposed mechanism for disease development. *Cells* 9.
- Wylie, S.A., Ridderinkhof, K.R., Bashore, T.R., Van Den Wildenberg, W.P., 2010. The effect of parkinson's disease on the dynamics of on-line and proactive cognitive control during action selection. *J. Cogn. Neurosci.* 22, 2058–2073.
- Zhang, D., He, X., Huang, S., Li, Y., 2001. Effect of manganese exposure on brain development in postnatal mice. *Wei Sheng Yan Jiu* 30, 260–262.